Yeonsoo Baik

Yeonsoo Baik

Auto-generated profile, based on publicly available information

Yeonsoo Baik

Department of International Health and

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
YBYeonsoo Baik
Yeonsoo Baik
HRHannah M. Rickman
Hannah M. Rickman
CHColleen F. Hanrahan
Colleen F. Hanrahan
LMLesego Mmolawa
Lesego Mmolawa
PKPeter J. Kitonsa
Peter J. Kitonsa
DDDavid W. Dowdy
David W. Dowdy
Background: In highly resource-limited settings, many clinics lack same-day microbiological testing for active tuberculosis (TB). In these contexts, risk of pretreatment loss to follow-up is high, and a simple, easy-to-use clinical risk score could be useful. Methods and findings: We analyzed data from adults tested for TB with Xpert MTB/RIF across 28 primary health clinics in rural South Africa (between July 2016 and January 2018). We used least absolute shrinkage and selection operator regression to identify characteristics associated with Xpert-confirmed TB and converted coefficients into a simple score. We assessed discrimination using receiver operating characteristic (ROC) curves, calibration using Cox linear logistic regression, and clinical utility using decision curves. We validated the score externally in a population of adults tested for TB across 4 primary health clinics in urban Uganda (between May 2018 and December 2019). Model development was repeated de novo with the Ugandan population to compare clinical scores. The South African and Ugandan cohorts included 701 and 106 individuals who tested positive for TB, respectively, and 686 and 281 randomly selected individuals who tested negative. Compared to the Ugandan cohort, the South African cohort was older (41% versus 19% aged 45 years or older), had similar breakdown of biological sex (48% versus 50% female), and had higher HIV prevalence (45% versus 34%). The final prediction model, scored from 0 to 10, included 6 characteristics: age, sex, HIV (2 points), diabetes, number of classical TB symptoms (cough, fever, weight loss, and night sweats; 1 point each), and >14-day symptom duration. Discrimination was moderate in the derivation (c-statistic = 0.82, 95% CI = 0.81 to 0.82) and validation (c-statistic = 0.75, 95% CI = 0.69 to 0.80) populations. A patient with 10% pretest probability of TB would have a posttest probability of 4% with a score of 3/10 versus 43% with a score of 7/10. The de novo Ugandan model contained similar characteristics and performed equally well. Our study may be subject to spectrum bias as we only included a random sample of people without TB from each cohort. This score is only meant to guide management while awaiting microbiological results, not intended as a community-based triage test (i.e., to identify individuals who should receive further testing). Conclusions: In this study, we observed that a simple clinical risk score reasonably distinguished individuals with and without TB among those submitting sputum for diagnosis. Subject to prospective validation, this score might be useful in settings with constrained diagnostic resources where concern for pretreatment loss to follow-up is high.

2 July 2021 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
YBYeonsoo Baik
Yeonsoo Baik
CHColleen F Hanrahan
Colleen F Hanrahan
LMLesego Mmolawa
Lesego Mmolawa
BNBareng A S Nonyane
Bareng A S Nonyane
NANicholas W Albaugh
Nicholas W Albaugh
DDDavid W Dowdy
David W Dowdy
Providing incentives to screen close contacts for tuberculosis (TB) is an alternative to household-based contact investigation. We aimed to characterize patients and contexts where this incentive-based strategy might be preferred. This is a secondary analysis of a cluster randomized trial of TB contact investigation in Limpopo District, South Africa, conducted between 2016 and 2020. Twenty-eight clinics were randomly allocated to household-based vs incentive-based contact investigation. In the incentive-based arm, index participants and contacts received transport reimbursement and incentives for TB screening and microbiological diagnosis of contacts. We estimated differences in mean number of contacts per index participant with household-based vs incentive-based contact investigation overall and within subgroups of index participants. A total of 3776 contacts (1903 in the incentive-based and 1873 in the household-based arm) were referred by 2501 index participants. A higher proportion of contacts in the incentive-based than household-based arm were adults (72% vs 59%), reported chronic TB symptoms (25% vs 16%) or ever smoking (23% vs 11%). Index participants who walked or bicycled to a clinic referred 1.03 more contacts per index (95% confidence interval [CI], .48 to 1.57) through incentive-based than household-based investigation. Index participants living with >5 household members referred 0.48 more contacts per index (95% CI, .03 to .94) through household-based than incentive-based investigation. Relative to household-based investigation, incentive-based investigation identifies contacts likely at higher risk for active TB. Incentive-based investigation may be more appropriate for index participants who can easily access clinics, versus household-based investigation for patients with large households. Clinical Trials Registration. NCT02808507.

24 October 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
AMAllan Musinguzi
Allan Musinguzi
JKJoan R. Kasidi
Joan R. Kasidi
JKJillian L. Kadota
Jillian L. Kadota
FWFred Welishe
Fred Welishe
ANAnne Nakitende
Anne Nakitende
AKAnne R. Katahoire
Anne R. Katahoire
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment of 3HP delivery nested within the 3HP Options Trial, which compared three optimized strategies for delivering 3HP: facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), and patient choice between facilitated DOT and facilitated SAT at the Mulago HIV/AIDS clinic in Kampala, Uganda. We conducted 72 in-depth interviews among PLHIV purposively selected to investigate factors influencing 3HP acceptance and completion. We conducted ten key informant interviews with healthcare providers (HCPs) involved in 3HP delivery to identify facilitators and barriers at the clinic level. We used post-trial 3HP delivery data to assess sustainability. We used thematic analysis (inductive and deductive) to align the emergent themes with the RE-AIM framework dimensions to report implementation outcomes. Understanding the need for TPT, once-weekly dosing, shorter duration, and perceived 3HP safety enhanced acceptance overall. Treatment monitoring by HCPs and reduced risk of HIV status disclosure enabled DOT acceptance. Dosing autonomy enabled SAT acceptance. Switching between DOT and SAT as needed enabled acceptance of patient choice. Dosing reminders, reimbursement for clinical visits, and social support enabled 3HP completion; pill burden, side effects, and COVID-19-related treatment restrictions hindered completion. All HCPs were trained and participated in 3HP delivery with high fidelity. Training, care integration, prior TPT experience with daily isoniazid, and few 3HP-related serious adverse events enabled adoption, whereas initial concerns about 3HP safety among HCPs, and COVID-19 treatment disruptions delayed 3HP adoption. Refresher training and collaboration among HCPs enabled implementation whereas limited diagnostic facilities for adverse events at the clinic hindered implementation. SAT was modified post-trial; DOT was discontinued due to inadequate ongoing financial support beyond the study period. Facilitated delivery strategies made 3HP treatment convenient for PLHIV and were feasible and implemented with high fidelity by HCPs. However, the costs of 3HP facilitation may limit wider scale-up. Trial registration: ClinicalTrials.gov (NCT03934931); Registered 2nd May 2019; https://clinicaltrials.gov/study/NCT03934931?id = NCT03934931&rank = 1.

22 August 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AMAllan Musinguzi
Allan Musinguzi
JKJoan R. Kasidi
Joan R. Kasidi
JKJillian L. Kadota
Jillian L. Kadota
FWFred Welishe
Fred Welishe
ANAnne Nakitende
Anne Nakitende
AKAnne R. Katahoire
Anne R. Katahoire
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment of 3HP delivery nested within the 3HP Options Trial, which compared three optimized strategies for delivering 3HP: facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), and patient choice between facilitated DOT and facilitated SAT at the Mulago HIV/AIDS clinic in Kampala, Uganda. We conducted 72 in-depth interviews among PLHIV purposively selected to investigate factors influencing 3HP acceptance and completion. We conducted ten key informant interviews with healthcare providers (HCPs) involved in 3HP delivery to identify facilitators and barriers at the clinic level. We used post-trial 3HP delivery data to assess sustainability. We conducted an inductive thematic analysis and aligned the emergent themes with the RE-AIM framework dimensions to report implementation outcomes. Understanding the need for TPT, once-weekly dosing, shorter duration, and perceived 3HP safety enhanced acceptance overall. Treatment monitoring by HCPs and reduced risk of HIV status disclosure enabled DOT acceptance. Dosing autonomy enabled SAT acceptance. Switching between DOT and SAT as required enabled acceptance for patient choice. Dosing reminders, reimbursement for clinical visits, and social support enabled 3HP completion; pill burden, side effects, and COVID-19-related treatment restrictions hindered completion. All HCPs were trained and participated in 3HP delivery with high fidelity. Training, care integration, and collaboration among HCPs enabled, whereas initial concerns about 3HP safety among HCPs delayed 3HP adoption and implementation. SAT was maintained post-trial; DOT was discontinued due to inadequate ongoing financial support beyond the study period. Facilitated delivery strategies made 3HP treatment convenient for PLHIV and were feasible and implemented with high fidelity by HCPs. However, the costs of 3HP facilitation may limit wider scale-up.

1 October 2025 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
YBYeonsoo Baik
Yeonsoo Baik
MMMuhammad Musoke
Muhammad Musoke
ATAmon Twinamasiko
Amon Twinamasiko
MLMaureen Lamunu
Maureen Lamunu
VNVivian Nabacwa
Vivian Nabacwa
DDDavid W. Dowdy
David W. Dowdy
Rationale: Undertreatment of tuberculosis (TB) is common in resource-limited settings where same-day microbiological diagnosis is unavailable. Objectives: We evaluated if a simple clinical risk score for predicting active TB could facilitate treatment initiation among individuals at high risk for TB. Methods: We conducted a pragmatic, implementation-effectiveness study in periurban primary health clinics in Uganda. Four intervention clinics were paired with standard-of-care comparison clinics. Providers in intervention clinics were trained to use the score and set a threshold score for considering same-day treatment initiation; treatment decisions were at the providers’ discretion. Our primary effectiveness outcome was the change in the proportion of individuals with confirmed TB who started on treatment within 7 days of presentation, comparing preintervention and postintervention periods. Results: Among intervention clinics, 594 (83%) of 720 people diagnosed with TB started treatment within 7 days during the preintervention period versus 264 (84%) of 316 after implementation (pre–post difference, 1%; 95% confidence interval [95% CI], −6%, 8%). In comparison clinics, 7-day treatment initiation changed from 312 (86%) of 363 preintervention to 153 (73%) of 211 postintervention (pre–post difference, −13%; 95% CI, −22, −5%). A difference-in-differences estimate was 14% (95% CI, 10%, 19%). In intervention clinics, 1,206 (66%) of 1,826 people presenting with TB symptoms were administered the risk score. Two hundred twenty-nine (19%) had a score above the treatment threshold, and 105 (46%) initiated treatment on the same day. Conclusions: An easy-to-use clinical risk score did not increase 7-day empiric treatment initiation in intervention clinics. However, it improved rapid treatment initiation relative to clinics using the prevailing standard of care. The score was also highly acceptable to clinical providers. Clinical trial registered with www.clinicaltrials.gov (NCT 05122624).